Comparison of 3 Tesla MRI to 7 Tesla MRI for Evaluation of Prostate Suspicion Lesions
A comparison of 3 Tesla MRI to 7 Tesla MRI for Evaluation of Prostate Suspicious Lesions.
Assess the added diagnostic value of ultra-high-field (7T) MRI over the current clinical standard (3T MRI) in detecting and characterizing suspicious prostate lesions. Evaluate whether dynamic deuterated glucose-enhanced imaging at 7T can offer improved contrast without the use of gadolinium-based agents.
調査の概要
詳細な説明
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Shai Efrati, MD
- 電話番号:972549212866
- メール:efratishai@outlook.com
研究場所
-
-
Israel
-
Zrifin、Israel、イスラエル、70300
- The Sagol Center for Hyperbaric Medicine and Research Shamir Medical Center (Assaf Harofeh)
-
コンタクト:
- Shai Efrati, Prof
- 電話番号:+972-8-9779393
- メール:efratishai@outlook.com
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- male patients referred for clinical 3T prostate MRI at Shamir Medical Center
- male patients who consent to undergo an additional 7T scan at the Weizmann Institute.
Exclusion Criteria:
- Contraindications to MRI (e.g., non-compatible implants, pacemakers, severe claustrophobia)
- diabetes mellitus
- glucose intolerance
- hyperglycemia
- hyperlactatemia
- chronic kidney disease (GFR <45 mL/min/1.73 m2).
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:診断
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:3 Tesla (3T) versus 7 Tesla (7T) MRI in the assessment of suspicious prostate lesions
Each participant serves as their own control, undergoing both 3T and 7T MRI scans.
|
Imaging protocols will include multiparametric sequences at both field strengths, with the addition of high-resolution anatomical and optional dynamic glucose-enhanced imaging at 7T.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
ROC analysis of diagnostic performance: 3T versus 7T MRI
時間枠:Assessed at the time of MRI acquisition during the study imaging visit.
|
ROC analysis (Receiver Operating Characteristic analysis) - A statistical method used to evaluate and compare diagnostic accuracy.
It examines how well a test distinguishes between diseased and non-diseased cases across different thresholds.
|
Assessed at the time of MRI acquisition during the study imaging visit.
|
|
Sensitivity and Specificity of diagnostic performance: 3T versus 7T MRI
時間枠:Assessed at the time of MRI acquisition during the study imaging visit.
|
Sensitivity - The ability of the MRI to correctly identify patients who truly have disease (true positive rate). High sensitivity means fewer missed cases. Specificity - The ability of the MRI to correctly identify patients who do not have disease (true negative rate). High specificity means fewer false alarms or false positives. |
Assessed at the time of MRI acquisition during the study imaging visit.
|
|
Lesion conspicuity of diagnostic performance: 3T versus 7T MRI
時間枠:Assessed at the time of MRI acquisition during the study imaging visit.
|
How clearly and visibly an abnormal lesion can be seen on MRI images compared with surrounding tissue.
Higher conspicuity generally makes lesions easier to detect and characterize.
|
Assessed at the time of MRI acquisition during the study imaging visit.
|
|
PI-RADS classification - The Prostate Imaging Reporting and Data System: 3T versus 7T MRI
時間枠:Assessed at the time of MRI acquisition during the study imaging visit.
|
a standardized scoring system used in prostate MRI to estimate the likelihood of clinically significant prostate cancer.
Scores range from 1 (very low likelihood) to 5 (very high likelihood).
|
Assessed at the time of MRI acquisition during the study imaging visit.
|
|
Quantitative imaging metrics of diagnostic performance: 3T versus 7T MRI
時間枠:Assessed at the time of MRI acquisition during the study imaging visit.
|
Numerical measurements derived from MRI images, such as lesion size, signal intensity, contrast ratios, diffusion values (e.g., ADC), or texture features, used to objectively compare imaging performance.
|
Assessed at the time of MRI acquisition during the study imaging visit.
|
協力者と研究者
捜査官
- 主任研究者:Shai Efrati、Asaf-Harofhe MC
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。